ACE inhibitors, AIIRA
The dual blockade of the RAA-system through the combined use of ACE-inhibitors, AIIRA or aliskiren is associated with a higher frequency of adverse events such as hypotension, hyperkalaemia and decreased renal function (including acute renal failure)
ACE inhibitors, AIIRA ---> SmPC of [azilsartan medoxomil] of EMA
The dual blockade of the RAA-system through the combined use of ACE-inhibitors, AIIRA or aliskiren is associated with a higher frequency of adverse events such as hypotension, hyperkalaemia and decreased renal function (including acute renal failure)
Aceclofenac [1], AIIRA ---> SmPC of [1] of eMC
NSAID's may reduce the effect of antihypertensives. The risk of acute renal insufficiency, which is usually reversible, may be increased in some patients with compromised renal function angiotensin II receptor antagonists are combined with NSAIDs.
Acemetacine, AIIRA
The co-administration may decrease the antihypertensive effect, increase the risk of renal failure and cause hypercaliemia. The concomitant use should be done with caution
Acetylsalicylic acid, AIIRA ---> SmPC of [irbesartan] of EMA
The combination of AIIRAs and AIIRAs (selective COX-2 inhibitors, ASA (> 3 g/day) and non-selective NSAIDs) may decrease the antihypertensive effect, increase the renal failure risk and cause hypercaliemia
AIIRA, phenylbutazone --->
The combination of AIIRAs and AIIRAs (selective COX-2 inhibitors, ASA (> 3 g/day) and non-selective NSAIDs) may decrease the antihypertensive effect, increase the renal failure risk and cause hypercaliemia
AIIRA, aliskiren [2] ---> SmPC of [2] of EMA
The dual blockade of the RAA-system through the combined use of ACE-inhibitors, AIIRA or aliskiren is associated with a higher frequency of adverse events such as hypotension, hyperkalaemia and decreased renal function (including acute renal failure)
AIIRA, aliskiren/amlodipine [2] ---> SmPC of [2] of EMA
The dual blockade of the RAA-system through the combined use of ACE-inhibitors, AIIRA or aliskiren is associated with a higher frequency of adverse events such as hypotension, hyperkalaemia and decreased renal function (including acute renal failure)
AIIRA, aliskiren/amlodipine/hydrochlorothiazide [2] ---> SmPC of [2] of EMA
The dual blockade of the RAA-system through the combined use of ACE-inhibitors, AIIRA or aliskiren is associated with a higher frequency of adverse events such as hypotension, hyperkalaemia and decreased renal function (including acute renal failure)
AIIRA, aliskiren/hydrochlorothiazide [2] ---> SmPC of [2] of EMA
The dual blockade of the RAA-system through the combined use of ACE-inhibitors, AIIRA or aliskiren is associated with a higher frequency of adverse events such as hypotension, hyperkalaemia and decreased renal function (including acute renal failure)
AIIRA, amiloride
When amiloride hydrochloride is administered concomitantly with an angiotensin II receptor antagonist the risk of hyperkalaemia may be increased.
AIIRA, amiloride/hydrochlorothiazide
When amiloride hydrochloride is administered concomitantly with an angiotensin II receptor antagonist the risk of hyperkalaemia may be increased.
AIIRA, amlodipine/valsartan [2] ---> SmPC of [2] of EMA
Dual blockade of the RAAS through the combined use of ACE inhibitors, ARBs or aliskiren is associated with a higher frequency of adverse events such as hypotension, hyperkalaemia and decreased renal function (including acute renal failure)
AIIRA, amlodipine/valsartan/hydrochlorothiazide ---> SmPC of [amlodipine/valsartan/hydrochlorothiazide] of EMA
The dual blockade of the RAA-system through the combined use of ACE-inhibitors, AIIRA or aliskiren is associated with a higher frequency of adverse events such as hypotension, hyperkalaemia and decreased renal function (including acute renal failure)
AIIRA, angiotensin II [2] ---> SmPC of [2] of EMA
Patients who have recently received angiotensin II receptor blockers (ARBs) may be less sensitive to GIAPREZA's actions with a reduced response.
AIIRA, antihypertensives
Additive hypotensive effect
AIIRA, bemetizide
The co-administration may increase the antihypertensive effects
AIIRA, betablockers
When combined with beta-blockers, drugs that decrease arterial pressure can cause or increase hypotension, notably orthostatic.
AIIRA, bosutinib [2] ---> SmPC of [2] of EMA
Long-term treatment with bosutinib may result in a clinically significant decline in renal function. Particular attention should be given to patients using medicinal products with potential for nephrotoxicity
AIIRA, breast-feeding
The lactation is not recommended
AIIRA, bupivacaine/meloxicam [2] ---> SmPC of [2] of EMA
NSAIDs may decrease the antihypertensive effect of ACE inhibitors, angiotensin-II antagonists, or beta-blockers (including propranolol).
AIIRA, celecoxib [2] ---> SmPC of [2] of EMA
The co-administration may decrease the antihypertensive effect and increase the risk of renal failure
AIIRA, clonazepam
Enhanced hypotensive effect
AIIRA, coxibs ---> SmPC of [parecoxib] of EMA
In patients with compromised renal function, co-administration of NSAIDs with ACE inhibitors or Angiotensin-II antagonists, may result in further deterioration of renal function, including possible acute renal failure.
AIIRA, cyclooxygenase inhibitors ---> SmPC of [flurbiprofen] of eMC
In some patients with compromised renal function the co-administration of an angiotensin II antagonist and agents that inhibit cyclo-oxygenase may result in further deterioration of renal function, including possible acute renal failure
AIIRA, cyclosporine [2] ---> SmPC of [2] of eMC
Caution is required with concomitant use of ciclosporin with potassium-sparing medicinal products or potassium-containing medicinal products since they may lead to significant increases in serum potassium
AIIRA, daclatasvir [2] ---> SmPC of [2] of EMA
No clinically relevant effects on the pharmacokinetics of either medicinal product are expected when daclatasvir is coadministered with angiotensin II receptor antagonists
AIIRA, dasabuvir with ombitasvir/paritaprevir/ritonavir ---> SmPC of [ombitasvir/paritaprevir/ritonavir] of EMA
CYP3A4 and/or OATP1B inhibition by paritaprevir. Clinical monitoring and dose reduction is recommended for angiotensin receptor blockers when co-administered with Viekirax with or without dasabuvir.
AIIRA, dexibuprofen [2] ---> SmPC of [2] of eMC
As with other NSAIDs, concomitant treatment with drugs increasing potassium plasma levels, may be associated with increased serum potassium levels and may increase the risk of renal failure
AIIRA, dexketoprofen [2] ---> SmPC of [2] of eMC
In some patients with compromised renal function, the coadministration may result in further deterioration of renal function, which is usually reversible.
AIIRA, diazepam [2] ---> SmPC of [2] of eMC
Enhanced hypotensive effect
AIIRA, dronedarone [2] ---> SmPC of [2] of EMA
No interaction was observed between dronedarone and losartan and an interaction between dronedarone and other AIIRAs is not expected.
AIIRA, drospirenone
Possible increase of potassium plasma concentrations.
AIIRA, enalapril/hydrochlorothiazide
Dual blockade with ACE inhibitors, ARA II or aliskiren is associated with a higher frequency of hypotension, syncope, hyperkalaemia, and worsening renal function (including acute renal failure). Concomitant use not recommended
AIIRA, eplerenone [2] ---> SmPC of [2] of eMC
The risk of hyperkalaemia may increase when eplerenone is used in combination with an angiotensin receptor blocker (ARB). A close monitoring of serum potassium and renal function is recommended
AIIRA, ertugliflozin/metformin [2] ---> SmPC of [2] of EMA
Some medicinal products can adversely affect renal function, which may increase the risk of lactic acidosis
AIIRA, etoricoxib [2] ---> SmPC of [2] of eMC
The co-administration of an Angiotensin II antagonist and agents that inhibit cyclo-oxygenase may result in further deterioration of renal function, including possible acute renal failure, which is usually reversible.
AIIRA, felodipine/ramipril
The dual blockade of the RAA-system through the combined use of ACE-inhibitors, AIIRA or aliskiren is associated with a higher frequency of adverse events such as hypotension, hyperkalaemia and decreased renal function (including acute renal failure)
AIIRA, flurbiprofen [2] ---> SmPC of [2] of eMC
In some patients with compromised renal function the co-administration of an angiotensin II antagonist and agents that inhibit cyclo-oxygenase may result in further deterioration of renal function, including possible acute renal failure
AIIRA, fosinopril
The dual blockade of the RAA-system through the combined use of ACE-inhibitors, AIIRA or aliskiren is associated with a higher frequency of adverse events such as hypotension, hyperkalaemia and decreased renal function (including acute renal failure)
AIIRA, furosemide [2] ---> SmPC of [2] of eMC
A marked fall in blood pressure and deterioration in renal function
AIIRA, general anesthetics
Enhanced hypotensive effect when general anaesthetics given with angiotensin-II receptor antagonists.
AIIRA, heparin ---> SmPC of [sodium heparin] of eMC
Combined use of heparin with ACE inhibitors or angiotensin II antagonists may increase the risk of hyperkalaemia.
AIIRA, hydrochlorothiazide ---> SmPC of [amlodipine/valsartan/hydrochlorothiazide] of EMA
Thiazides potentiate the antihypertensive action of other antihypertensive drugs
AIIRA, hyperkalemia
The combination may lead to hyperkalemia. Co-administration is not recommended
AIIRA, ibuprofen
The co-administration may cause a further worsening of renal function. The concomitant use should be done with caution
AIIRA, imidapril
The dual blockade of the RAA-system through the combined use of ACE-inhibitors, AIIRA or aliskiren is associated with a higher frequency of adverse events such as hypotension, hyperkalaemia and decreased renal function (including acute renal failure)
AIIRA, indometacin
The combination of AIIRAs and AIIRAs (selective COX-2 inhibitors, ASA (> 3 g/day) and non-selective NSAIDs) may decrease the antihypertensive effect, increase the renal failure risk and cause hypercaliemia
AIIRA, insulin
Possible reduction of the insulin requirements
AIIRA, insulin lispro [2] ---> SmPC of [2] of EMA
Insulin requirements may be reduced in the presence of medicinal products with hypoglycaemic activity
AIIRA, iobitridol
Decreased efficacy of cardiovascular compensation mechanisms that occur in blood pressure disorder
AIIRA, ioxaglic acid
Decreased efficacy of cardiovascular compensation mechanisms that occur in blood pressure disorder
AIIRA, irbesartan/hydrochlorothiazide [2] ---> SmPC of [2] of EMA
The co-administration may decrease the antihypertensive effect, increase the risk of renal failure and cause hypercaliemia. The concomitant use should be done with caution
AIIRA, ivabradine [2] ---> SmPC of [2] of EMA
In pivotal phase III clinical trials the angiotensin II antagonists were routinely combined with ivabradine with no evidence of safety concerns
AIIRA, ketoprofen [2] ---> SmPC of [2] of eMC
In patients with compromised renal function the co-administration of an angiotensin II antagonist and agents that inhibit cyclooxygenase may result in further deterioration of renal function, including possible acute renal failure.
AIIRA, ketorolac [2] ---> SmPC of [2] of eMC
The risk of acute renal insufficiency, which is usually reversible, may be increased in some patients with compromised renal function when angiotensin II receptor antagonists are combined with NSAIDs.
AIIRA, labetalol
Possible enhancement of hypotensive effect of labetalol
AIIRA, linagliptin/metformin [2] ---> SmPC of [2] of EMA
Special caution should be exercised in situations where renal function may become impaired. In these cases, it is recommended to check renal function before initiating treatment with metformin.
AIIRA, lisinopril
Dual blockade of the RAA system through the combined use of ACE-inhibitors, angiotensin II receptor blockers or aliskiren is associated with a higher frequency of adverse events such as hypotension, hyperkalaemia and decreased renal function
AIIRA, lisinopril/hydrochlorothiazide
The dual blockade of the RAA-system through the combined use of ACE-inhibitors, AIIRA or aliskiren is associated with a higher frequency of adverse events such as hypotension, hyperkalaemia and decreased renal function (including acute renal failure)
AIIRA, lithium ---> SmPC of [telmisartan] of EMA
Reversible increases in serum lithium concentrations and toxicity have been reported during concomitant administration of lithium with angiotensin II receptor antagonists
AIIRA, lithium carbonate [2] ---> SmPC of [2] of eMC
Increased lithium concentrations
AIIRA, lorazepam [2] ---> SmPC of [2] of eMC
Enhanced hypotensive effect
AIIRA, lornoxicam
Decreased antihypertensive efficacy
AIIRA, losartan/hydrochlorothiazide [2] ---> SmPC of [2] of eMC
The dual blockade of the RAA-system through the combined use of ACE-inhibitors, AIIRA or aliskiren is associated with a higher frequency of adverse events such as hypotension, hyperkalaemia and decreased renal function (including acute renal failure)
AIIRA, lumiracoxib
In some patients with compromised renal function the co-administration of an angiotensin II antagonist and agents that inhibit cyclo-oxygenase may result in further deterioration of renal function, including possible acute renal failure
AIIRA, meloxicam
The combination of AIIRAs and AIIRAs (selective COX-2 inhibitors, ASA (> 3 g/day) and non-selective NSAIDs) may decrease the antihypertensive effect, increase the renal failure risk and cause hypercaliemia
AIIRA, metformin/saxagliptin/dapagliflozin [2] ---> SmPC of [2] of EMA
Some medicinal products can adversely affect renal function which may increase the risk of lactic acidosis. When starting or using such product in combination with metformin, close monitoring of renal function is necessary.
AIIRA, midazolam
Enhanced hypotensive effect
AIIRA, nabumetone [2] ---> SmPC of [2] of eMC
Angiotensin-converting enzyme inhibitors (ACEI) and angiotensin receptor antagonists (ARA) may present with decreased effect when concomitantly administered with NSAID
AIIRA, naproxen [2] ---> SmPC of [2] of eMC
Concomitant administration of naproxen may reduce the antihypertensive effect and may increase the risk of renal impairment associated with the use of angiotensin II receptor antagonists.
AIIRA, naproxen/esomeprazole [2] ---> SmPC of [2] of eMC
NSAIDs may diminish the antihypertensive effect of angiotensin II receptor antagonists. NSAIDs may also increase the risk of renal impairment associated with the use of angiotensin II receptor antagonists.
AIIRA, nifedipine [2] ---> SmPC of [2] of eMC
Nifedipine may be used in combined therapy with other antihypertensive agents including beta-blocker drugs, but the possibility of an additive effect resulting in postural hypotension should be borne in mind.
AIIRA, nimesulide
The co-administration with long-term NSAIDs may decrease the antihypertensive effect and increase the risk of renal failure
AIIRA, nimodipine [2] ---> SmPC of [2] of eMC
Nimodipine may increase the blood pressure lowering effect of concomitant antihypertensives
AIIRA, nisoldipine
The co-administration may potentiate the hypotensive effect
AIIRA, nitrendipine
The co-administration may potentiate the hypotensive effect
AIIRA, NSAID ---> SmPC of [irbesartan] of EMA
The combination of AIIRAs and AIIRAs (selective COX-2 inhibitors, ASA (> 3 g/day) and non-selective NSAIDs) may decrease the antihypertensive effect, increase the renal failure risk and cause hypercaliemia
AIIRA, ombitasvir/paritaprevir/ritonavir [2] ---> SmPC of [2] of EMA
CYP3A4 and/or OATP1B inhibition by paritaprevir. Clinical monitoring and dose reduction is recommended for angiotensin receptor blockers when co-administered with Viekirax with or without dasabuvir.
AIIRA, parecoxib [2] ---> SmPC of [2] of EMA
Inhibition of prostaglandins by NSAIDs, including COX-2 inhibitors, may diminish the effect of angiotensin II antagonists
AIIRA, perindopril
The dual blockade of the RAA-system through the combined use of ACE-inhibitors, AIIRA or aliskiren is associated with a higher frequency of adverse events such as hypotension, hyperkalaemia and decreased renal function (including acute renal failure)
AIIRA, phenothiazines ---> SmPC of [fluphenazine] of eMC
Concurrent use of phenothiazines and angiotensin II antagonists may result in severe postural hypotension.
AIIRA, piroxicam
The co-administration of AIIRAs with long-term NSAIDs may decrease the antihypertensive effect, increase the risk of renal failure and cause hypercaliemia.
AIIRA, potassium
The combination may lead to hyperkalemia, particularly in renal failure. Co-administration is not recommended
AIIRA, potassium canrenoate
The co-administration may cause hyperpotassemia und is not recommended
AIIRA, potassium chloride [2] ---> SmPC of [2] of eMC
Combined treatment of potassium chloride with angiotensin-II-receptor antagonists increase the risk of hyperkalaemia
AIIRA, potassium-sparing diuretics ---> SmPC of [spironolactone] of eMC
The combination may lead to hyperkalemia, particularly in renal failure. Co-administration is not recommended
AIIRA, propranolol [2] ---> SmPC of [2] of EMA
When combined with beta-blockers, drugs that decrease arterial pressure can cause or increase hypotension, notably orthostatic.
AIIRA, quinapril
Dual blockade with ACE inhibitor, angiotensin-receptor blockers or aliskiren is associated with a higher frequency of hypotension, hyperkalaemia, and worsening renal function (including acute renal failure).
AIIRA, ramipril
The dual blockade of the RAA-system through the combined use of ACE-inhibitors, AIIRA or aliskiren is associated with a higher frequency of adverse events such as hypotension, hyperkalaemia and decreased renal function (including acute renal failure)
AIIRA, sacubitril/valsartan [2] ---> SmPC of [2] of EMA
Entresto contains valsartan, and therefore should not be co-administered with another ARB containing product
AIIRA, sitagliptin/metformin [2] ---> SmPC of [2] of EMA
There is increased risk of lactic acidosis in acute alcohol intoxication due to the metformin active substance of Efficib. Consumption of alcohol and medicinal products containing alcohol should be avoided
AIIRA, sodium heparin [2] ---> SmPC of [2] of eMC
Combined use of heparin with ACE inhibitors or angiotensin II antagonists may increase the risk of hyperkalaemia.
AIIRA, spironolactone [2] ---> SmPC of [2] of eMC
Concurrent administration of angiotensin-II receptor antagonists and spironolactone may result in an increase in serum potassium levels.
AIIRA, tadalafil [2] ---> SmPC of [2] of EMA
Tadalafil (10 mg except for studies with angiotensin II receptor blockers and amlodipine in which a 20 mg dose was applied) had no clinically significant interaction
AIIRA, thiazides ---> SmPC of [amlodipine/valsartan/hydrochlorothiazide] of EMA
Thiazides potentiate the antihypertensive action of other antihypertensive drugs
AIIRA, thiopental
Enhanced hypotensive effect when general anaesthetics given with angiotensin-II receptor antagonists.
AIIRA, tiaprofenic acid
The concomitant use may decrease the antihypertensive effects
AIIRA, triamterene
The co-administration may enhance the hypotensive effect and increase the risk of severe hyperkalaemia, particularly in renal failure
AIIRA, valsartan
The dual blockade of the RAA-system through the combined use of ACE-inhibitors, AIIRA or aliskiren is associated with a higher frequency of adverse events such as hypotension, hyperkalaemia and decreased renal function (including acute renal failure)
AIIRA, zofenopril
Dual blockade of the RAAS through the combined use of ACE-inhibitors, AIIRAs or aliskiren is associated with a higher frequency of adverse events such as hypotension, hyperkalaemia and decreased renal function (including acute renal failure)